VRTX · News · 20260816N

Licensing / Collaboration Deals

VERTEX PHARMACEUTICALS INC / MA · 2026-08-16 · Importance 31 · Surprise 42

On August 16, 2026, Vertex Pharmaceuticals entered a new collaboration with AbCellera Biologics related to AbCellera’s ABCL635 menopause drug program. AbCellera reported positive Phase 2 results and a US$200 million equity raise, while the Vertex deal provides AbCellera with non-dilutive funding and a potential royalty stream. The report did not disclose the collaboration’s upfront payment, development obligations, geographic scope, or royalty rate.